ReviewAdvanced healthcare materials2026
Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review.
Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Functional hydrogel biomaterials for urological diagnosis and treatment-design strategies and application progress: a review.Journal of materials science. Materials in medicine · 2026Review
- Transforming Cancer Diagnosis and Therapy Through Fluorescent Hydrogels: A Review.Advanced healthcare materials · 2026Review
- Hydrogel-Based Monitoring in Perioperative Anesthesia: A Conceptual Review and Translational Perspective.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent decades have witnessed a revolution in oncological care and control, with new drug transport systems, advanced functional imaging, and next-generation biosensors. At the forefront of this revolution is the development of engineered hydrogels that intricately mimic the tumor microenvironment. These hydrogels are drawing significant attention in preclinical, diagnostic, and therapeutic applications in cancer. By integrating fluorescent agents, these hydrogels enable real-time tracking and enhanced imaging, paving the way for advancements in cancer diagnostics and therapeutic monitoring. Fluorescent hydrogel-based biosensors can monitor tumor bulk, assess tumor targeting by therapeutics, and distinguish between the initial and later effects of cancer treatment early in its progression. By encapsulating antibodies, biomarkers, or small molecules within fluorescent-labeled hydrogel structures, these systems achieve unprecedented levels of detection and imaging precision. Fluorescent hydrogels are also utilized to deliver chemotherapeutic drugs, immunosuppressants, hyperthermia-inducing agents, photodynamic therapy compounds, and other therapeutics, enabling localized, on-demand controlled release for cancer treatment and drug release monitoring. This review examines the methods for fluorescent labeling of hydrogels and explores the latest applications of fluorescent hydrogels in cancer treatment, biorecognition, and visualization. Finally, it discusses the primary challenges and potential future progression of fluorescent hydrogels for cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.